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Targeted resequencing identifies genes with recurrent variation
in cerebral palsy
C. L. van Eyk 1,2, M. A. Corbett 1,2, M. S. B. Frank 1,2, D. L. Webber1,2, M. Newman3, J. G. Berry 1,2, K. Harper1,2, B. P. Haines1,2,
G. McMichael1,2, J. A. Woenig1,2, A. H. MacLennan1,2 and J. Gecz 1,2,4*
A growing body of evidence points to a considerable and heterogeneous genetic aetiology of cerebral palsy (CP). To identify
recurrently variant CP genes, we designed a custom gene panel of 112 candidate genes. We tested 366 clinically unselected
singleton cases with CP, including 271 cases not previously examined using next-generation sequencing technologies. Overall, 5.2%
of the naïve cases (14/271) harboured a genetic variant of clinical significance in a known disease gene, with a further 4.8% of
individuals (13/271) having a variant in a candidate gene classified as intolerant to variation. In the aggregate cohort of individuals
from this study and our previous genomic investigations, six recurrently hit genes contributed at least 4% of disease burden to CP:
COL4A1, TUBA1A, AGAP1, L1CAM, MAOB and KIF1A. Significance of Rare VAriants (SORVA) burden analysis identified four genes with
a genome-wide significant burden of variants, AGAP1, ERLIN1, ZDHHC9 and PROC, of which we functionally assessed AGAP1 using a
zebrafish model. Our investigations reinforce that CP is a heterogeneous neurodevelopmental disorder with known as well as novel
genetic determinants.
npj Genomic Medicine            (2019) 4:27 ; https://doi.org/10.1038/s41525-019-0101-z
INTRODUCTION
Cerebral palsy (CP) is the most common motor disability of
childhood, with a frequency of around 2 per 1000 live births.1,2 CP
encompasses a clinically heterogeneous spectrum of disorders of
movement, posture or motor function, which are collectively
defined by being permanent and non-progressive. These dis-
orders are the result of a lesion or abnormality in the developing
brain occurring in the antenatal, perinatal or early postnatal
period. Variable patterns of neuropathology are observed on brain
imaging, and for most cases the aetiology of the brain injury is not
well understood. A number of neurodevelopmental problems
frequently co-occur with CP, including intellectual disability (ID),
autism spectrum disorder (ASD), epilepsy and visual and hearing
impairment.
A number of observations have long suggested a likely genetic
contribution to CP: the increased concordance rate for CP in
monozygotic twins compared to dizygotic twins,3 the higher risk
of CP in consanguineous families4–6 and the frequent co-
occurrence of CP with comorbidities with known genetic
contribution. Causative gene variants have been identified in
large CP pedigrees.7–11
Recent studies utilising genome-wide arrays12–14 and next-
generation sequencing technologies15–18 have begun to unravel
the genetic contribution to CP. In sporadic cases, the majority of
causative variants have been shown to be de novo, a trend that is
also observed in other neurodevelopmental disorders such as ID
and epilepsy.19,20 Whole-exome sequencing (WES) studies to date
have reported varying diagnostic rates, seemingly at least partly
dependent upon the clinical selection criteria used, ranging from
14% in our clinically unselected cohort,15 to up to 57% of cases in
homogenous cohorts with extensive prior work-up.16,17 The
modest reported diagnostic rate reported in McMichael et al.15
is likely also due in part to the stringent criteria used to select
causative variants.
The interpretation of genetic variants in CP is complicated by
the fact that the majority of the cases are singletons and that CP
encompasses a range of movement problems of variable clinical
severity, with or without comorbidities. Consequently, large
cohorts of sporadic cases need to be sequenced before a gene
achieves sufficient hits for significance to be supported through,
for example, burden analysis.21 In light of this, we designed a
custom CP gene panel also including selected candidate CP genes
from the literature (Supplementary Table 1) with the aim of
identifying recurrently variant CP genes. Here we report the results
of this effort of resequencing of 366 CP cases, including 95 cases
previously tested by WES.
RESULTS
In total, we analysed 403 CP cases using our custom-designed
gene panel, including re-screening 97 cases previously examined
by WES to compare the detection rate of known and novel
variants for the 112 genes in the HaloPlex gene panel. Overall, a
median of 96.7% (minimum 86.5%, maximum 99.2%) of targeted
bases were covered by at least 20 reads across all samples, with a
median of 98.9% (minimum 95.2%, maximum 99.7%) of targeted
regions covered by at least 20 reads across all samples
(Supplementary Table 2, Supplementary Fig. 1). For the 97 samples
previously examined by WES, we also calculated coverage across
the regions targeted by the HaloPlex gene panel (Supplementary
Fig. 2). We achieved median coverage of 355.5× coverage of
targeted regions with the HaloPlex gene panel across these
samples, compared to median coverage of 75.6× for these same
target regions by WES. A total of 37 samples of the 403 cases
(including two samples previously examined by WES) were
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excluded from further analysis after failing quality control (>50%
of targeted bases with <20× coverage), therefore the final number
of samples analysed was 366, including 271 naïve cases and 95 re-
sequenced cases. Principal Component Analysis did not demon-
strate bias in coverage of targeted regions when either sample
type (buccal or Lymphoblastoid cell line) or sequencing platform
were considered (Supplementary Fig. 3).
Variants detected in samples that passed quality control were
filtered for likely pathogenicity as described in Methods. Prioritised
variants validated in this study are listed in Supplementary Tables
3–5. We validated a total of 135 variants in 103 new cases,
therefore 103/271 new cases (38%) in this study had at least one
variant of interest (Supplementary Table 5). Considering cases
sequenced with both technologies, the HaloPlex gene panel and
WES technologies together detected 76 high-quality variants in 95
cases. Of these 76 variants, 69 were identified by WES, while a total
of 70 variants were detected using the HaloPlex gene panel,
including seven variants not covered by the WES data. Two
variants detected by WES were not called by SureCall, but manual
inspection showed that they were covered, and an additional four
variants were not covered well by this gene panel, including two
pathogenic variants in TUBA1A. Therefore, if we consider the joint
set of high-quality variants detected in these 95 samples from WES
plus HaloPlex as the ‘gold-standard’, the gene panel approach
successfully identified 70/76 variants, achieving comparable
sensitivity to WES, which identified 69/76 variants.
We identified 23 individuals (6% of the 366 cases) with variants
of potential clinical relevance in genes associated with other
disorders (Table 1, Supplementary Table 6). Of these, seven
individuals harboured variants that were classified as pathogenic,
and a further two as likely pathogenic according to ACMG
guidelines.22 We have previously reported two of these variants
(Table 1 and ref. 15): a likely pathogenic de novo variant in MAST1
in P009 (NM_014975.3: c.1499C>T: p.P500L) and a de novo
pathogenic variant in KDM5C in P026 (NM_001146702.1:
c.1238C>T: p.P413L). For an additional two individuals, the variants
were detected by WES but were not classified as pathogenic at the
time of the analysis. These variants are a pathogenic COL4A1
variant in P033 (NM_001845.5: c.2413G>A: p.G805R) and com-
pound heterozygous pathogenic variants in the protein C gene,
PROC (NM_000312.3: c.169C>T: p.R57W / NM_000312.3: c.814C>T:
p.R272C) in P052. For P033, we have also reported a de novo splice
site variant in AGAP1, which was predicted to be likely pathogenic
(Table 2 and ref. 15). One individual with the COL4A1 p.G805R
variant has previously been reported: a 25-year-old male who,
following infantile hemiparesis, had repeated deep intracerebral
haemorrhages from 17 years of age.23 The contribution of each of
these variants requires further investigation, particularly given the
reported clinical heterogeneity and reduced penetrance of
COL4A1 mutations.24 In the case of P052, the subsequent
availability of further clinical information revealed a family history
of progressive neurodevelopmental decline and death from an
obscure degenerative leuko-encephalopathy in two female
siblings of the proband. P052 had a complex clinical phenotype,
with mixed spastic/dyskinetic quadriplegic CP, epilepsy, mild ID
and a diagnosis of possible Gardner–Diamond syndrome at
Table 1. Cases with variants of possible clinical significance in known disease genes
Sample Gene Inheritance gnomAD frequency Variant dbSNP ID, ACMG classification
P009a MAST1 De novo 0 c.1499C>T:p.P500Lb Likely pathogenic
P015a PAK3 X-linked 0 c.1477C>T:p.R493Cb Uncertain significance
P026a KDM5C De novo 0 c.1238C>T:p.P413Lb rs1057518697 Pathogenic
P033a COL4A1 Paternal 0 c.2413G>A:p.G805R Pathogenic
P035a COL4A1 Not maternal 8.12E−06 c.136G>A:p.G46R Uncertain significance
P052a PROC Paternal 2.53E−05 c.169C>T:p.R57W rs757583846 Pathogenic
Maternal 2.53E−05 c.814C>T:p.R272C rs121918154 Pathogenic
P106a COL4A1 Paternal 0 c.4516A>G:p.N1506D Uncertain significance
P174 KIF1A Not maternal, father unavailable 0 c.296C>T:p.T99M rs387906799 Pathogenic
P204 COL4A1 Not maternal 0 c.2494G>A:p.G832R rs797044867 Pathogenic
P718 NT5C2 Homozygous—identical by descent 0 c.115C>T:p.R39* Pathogenic
P724 L1CAM X-linked 0 c.2137C>T:p.P713S Likely pathogenic
P773 MAST1 Not maternal 8.12E−06 c.1066G>A:p.D356N Uncertain significance
P781 KIF1A De novo 0 c.946C>T:p.R316W rs672601370 Pathogenic
P904 SCN8A De novo, also present in identical twin 4.06E−06 c.4724C>T:p.A1575V Uncertain significance
P915 HUWE1 Not maternal, also present in twin 5.60E−06 c.6391T>A:p.L2131M Likely benign
P968 BRWD3 Unknown 0 c.3088G>A:p.V1030I Uncertain significance
P981 COL4A1 Not maternal 6.63E−05 c.2447C>T:p.P816L Uncertain significance
P1102 HUWE1 Paternal 1.69E−05 c.8558A>T:p.E2853V Uncertain significance
P1116 COL4A1 Maternal 7.21E−05 c.4856G>A:p.R1619H Uncertain significance
P1147 IQSEC2 Paternal 0 c.1753C>T:p.R585W Likely benign
10249 HUWE1 Unknown 5.60E−06 c.6500C>T:p.A2167V Uncertain significance
10894 SYNGAP1 Not maternal 0 c.3436C>G:p.P1146A Uncertain significance
14986 MAST1 Paternal 1.44E−05 c.421G>A:p.E141K Uncertain significance
See Supplementary Table 6 for full version of this table including clinical information
gnomAD genome aggregation database frequency
*indicates translation termination codon
aCase reported in ref. 15
bVariant reported in ref. 15
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18 years of age. Periventricular cystic porencephaly with bilateral
frontal pachygyria was observed by magnetic resonance imaging
(MRI) at 2 years of age. Compound heterozygous mutations in
PROC have been previously associated with familial CP,25 with
clinical features including global developmental delay, cortical
visual blindness, spastic diplegia and recurrent purpura fulminans.
Brain MRIs typically show bilateral periventricular cystic porence-
phaly, with loss of cerebral white matter.
A further five individuals were naïve cases in whom we
identified a pathogenic or likely pathogenic genetic variant in a
known disease gene using the HaloPlex gene panel. Firstly, a
pathogenic COL4A1 variant (NM_001845.5: c.2494G>A: p.G832R)
was identified in P204, a male with choreoathetoid quadriplegia,
cystic porencephaly and epileptic encephalopathy. Two indivi-
duals, P174 and P781, had known pathogenic variants in KIF1A
(NM_004321.7: c.296C>T: p.T99M and NM_004321.7: c.946C>T: p.
R316W, respectively). P174 had spastic quadriplegic CP with
partial dysgenesis of the corpus callosum, global developmental
delay, epilepsy, scoliosis in the lumbar region and optic atrophy
resulting in cortical blindness. The KIF1A p.T99M variant identified
in P174 is a recurrent de novo variant previously reported in a
number of individuals with thin corpus callosum, cerebellar
atrophy and a progressive clinical course involving microcephaly,
severe global developmental delay, ID, cortical visual impairment,
hypotonia, hyperreflexia and variable features including optic
atrophy, spastic paraparesis and seizures.26–28 P781 had mixed
spastic/dystonic diplegic CP with intermittent hypertonicity,
microcephaly, developmental delay and cortical visual impair-
ment. Individuals with the KIF1A p.R316W variant identified in
P781 have also previously been reported.26,28 A homozygous
pathogenic stop-gain mutation in NT5C2, NM_001134373.2:
c.115C>T: p.R39*, was identified in a female, P718, who had
spastic diplegia, developmental delay, autism, attention deficit
hyperactivity disorder (ADHD), visual problems and severe
behavioural problems and was from a consanguineous family.
Autosomal recessive mutations in NT5C2 are the cause of spastic
paraplegia type 45 and are associated with ID.29 Finally, a novel X-
linked likely pathogenic variant was identified in L1CAM
(NM_001143963.2: c.2137C>T: p.P713S), mutations in which cause
CRASH syndrome (corpus callosum hypoplasia, retardation,
aphasia, spastic paraplegia and hydrocephalus). The affected
boy, P724, was born at term with antenatally diagnosed gross
ventriculomegaly, absent corpus callosum and thinning of the
cortical mantle. He presented with spastic diplegia, spastic
paraparesis and macrocephaly. One male cousin was also reported
with CP and three maternal aunts were confirmed carriers of the
mutation. A further nine naïve cases harboured variants of
uncertain significance in a known disease gene, and two cases
harboured variants that were likely benign (Table 1, Supplemen-
tary Table 6). Therefore, overall 14/271 (5.2%) of naïve cases
harboured a variant of potential clinical significance in a known
disease gene, with five of these classified as either pathogenic or
likely pathogenic.
Twenty-six individuals (Table 2, Supplementary Table 7)
harboured variants in candidate genes, which are predicted to
be intolerant to variation (Supplementary Table 1), thirteen of
whom were naïve cases in whom no other candidate variant was
identified. Therefore, excluding cases that we have previously
investigated using WES, 27/271 (10%) of individuals in this cohort
were found to harbour a variant of potential clinical relevance in
either a known disease gene, or a variation intolerant candidate
CP gene.
Two unrelated individuals were identified with a novel variant
of uncertain clinical significance in MAOB (NM_000898.5:
c.980C>T: p.T327M, Table 2). The first of these individuals, P216,
had X-linked inheritance of the variant from his unaffected
mother. He was born at term with seizures as a neonate and later
developed childhood epilepsy, spastic quadriplegia,
developmental delay, kyphoscoliosis, visual problems and pro-
gressive muscle weakening. The second, P915, was a female
monozygotic twin born at 35 weeks reported with spastic diplegia,
epilepsy and visual problems while her twin was developmentally
normal despite also carrying the MAOB variant. The variant was
confirmed not to be maternally inherited; however, the father was
unavailable for testing. We examined the ratio of X-chromosome
inactivation in blood-derived DNA for each twin and found no
evidence for non-random inactivation as an explanation for
clinical discordance; however, we cannot rule out tissue-specific
variation in X-inactivation ratios in this twin pair.
In order to determine the contribution of rare genetic variation
to CP aetiology, we assessed the frequency of rare genetic
variation in candidate genes in our new CP cohort of 271 cases
compared to 503 controls (all 503 individuals in the EUR cohort of
the 1000 Genomes Project) using Significance of Rare VAriants
(SORVA). SORVA analysis ranks genes based on their mutation
burden in a cohort of interest compared to controls, with the
assumption that fewer control individuals will carry rare, protein-
altering or loss-of-function variants in genes associated with the
disorder of interest. Therefore, while this analysis does not directly
assess pathogenicity of a variant, it provides a tool for prioritising
variants by quantifying the significance of seeing a variant within
a particular gene. We identified four genes for which the burden
of rare variants passed the threshold for genome-wide signifi-
cance (Table 3, Bonferroni corrected p-value < 0.05, Supplemen-
tary Table 8). These genes are AGAP1 (corrected p= 3.33E−04),
ERLIN1 (corrected p= 4.03E−03), ZDHHC9 (corrected p= 4.03E−03)
and PROC (corrected p= 4.59E−02). While supporting a role for
rare genetic variation in these genes in CP causation, we note that
the small available sample sizes for both cases and control in this
analysis, as well as the differences in sequencing platform and
coverage between the HaloPlex gene panel and 1000 genomes
data, are potential confounders and therefore further validation is
required.
To assess the pathogenicity of rare variants identified in CP
cases, we used the same criteria to examine regions covered in
our HaloPlex gene panel and annotated them for the 1000
genomes control data. We found no significant difference in the
distribution of CADD, SIFT or PolyPhen2 scores for rare variants in
our CP cohort compared to controls (Supplementary Fig. 4,
Supplementary Fig. 5), suggesting no overall increased burden of
deleterious variants. We next looked at the number of rare, likely
deleterious variants detected in each gene covered by the gene
panel (using criteria ExAC < 0.0001, 1000 g < 0.001, CADD Phred >
20). Six genes were identified with a significant overabundance of
rare, likely deleterious variants in CP cases compared to controls:
AGAP1 (p < 0.0001), COL4A1 (p= 0.0011), KIF1A (p < 0.0001), MAST1
(p= 0.0044), MTMR1 (p < 0.0001) and PCBP3 (p < 0.0001) (Fig. 1).
Using the machine learning tool DOMINO,30 we assessed the
likelihood of each of these genes being associated with a
dominant genetic disorder. Of the 5/6 genes that are located on
an autosome, three of these genes are predicted to be dominant
(KIF1A, COL4A1 and MAST1), while AGAP1 is predicted either
dominant or recessive.
Based on the significant burden of rare variants in AGAP1 to CP
in this cohort, the overabundance of predicted pathogenic
variants in CP cases compared to controls and the identification
of two de novo AGAP1 variants in CP to date (this study and
ref. 15), we investigated the functional consequences of knocking
down AGAP1 expression in a zebrafish model. AGAP1 is a regulator
of endosomal trafficking and AGAP1 expression levels have been
shown to inversely modulate dendritic spine density in hippo-
campal neuron cultures, suggesting that AGAP1 activity is highly
regulated to ensure correct development and maturation of
dendritic spines during development.31 We knocked down
expression of AGAP1 in zebrafish larvae and assessed gross
morphology at 24 hour post fertilisation (hpf), 48 hpf and 72 hpf
C. L. van Eyk et al.
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and motility and responses to light and tapping stimuli at 96 hpf.
Morphant zebrafish larvae showed a range of dosage-dependent,
early developmental phenotypes, including generalised develop-
mental delay and convergence extension defects with necrotic
tissue in the brain at 24 hpf (Fig. 2a, b). By 48 hpf, fish frequently
exhibited a curved tail phenotype of varying severity (Fig. 2a, c),
with some fish showing tail rigidity when stimulated by touch
(Supplementary Movie 1). AGAP1 morphant fish showed a
decrease in total activity compared to control larvae at 96 hpf, a
phenomenon which was rescued by co-injection of human AGAP1
mRNA (Fig. 2d), supporting a functional overlap between the
human and zebrafish orthologues. In addition, there was both a
qualitative and quantitative difference in the startle/escape
response of morphant fish at 96 hpf (Fig. 2e). Fewer AGAP1
morphant fish reacted to a tapping stimulus, which should elicit a
characteristic escape response. Of those that showed any
response, fewer fish responded with the fast, large angle burst
(C-turn), which is typical of zebrafish larvae when threatened.32
Additionally, in response to a light flash, morphant fish show a
dampened and delayed escape response, where all other groups
react with a statistically significant burst of activity (Fig. 2f, g).
Together these data support a neurological deficit in AGAP1
morphant fish, in addition to motility defects.
DISCUSSION
In this study, we sought to demonstrate the utility of a targeted
gene panel for genetic diagnosis of individuals with CP. Gene
panels have lower computational and economic costs, better
sequence coverage of specified targets and the potential for
higher confidence discovery of somatic mosaicism compared to
WES.33 They allow the relatively rapid assessment of larger cohorts
of individuals for recurrent variance, thereby providing support for
further investment in functional validation of specific genes or
variants. For genetically heterogeneous disorders, this is becoming
increasingly important as the pace of variant discovery using next-
generation sequencing technologies has far outstripped the pace
of functional genomics. Follow-up validation studies, for example
Sanger sequencing validation of variants and familial segregation
analysis, to confirm that variants are real and inherited in a pattern
consistent with the affected status in the family, as well as
functional validation of variants using animal or cell models,
remain major bottlenecks in the analysis of large cohorts of
patients.
Since relatively few genes from a limited number of studies
have so far been associated with CP, a definitive gene list is not yet
possible for CP. The gene list used in this study was derived from
published known and candidate CP genes from our studies and
those of others;8–11,15,25,34–40 however, this panel has flexibility to
be regularly updated with novel published CP genes. Since the
design of this gene panel, pathogenic variants in a number of
other genes have been identified in individuals with CP and future
designs should include these candidates; for example,
CTNNB1,18,41 PDCD6IP,42 AMPD2,18 ITPR1, KCNC3 and SPTBN2.17
Excluding cases previously investigated using WES, we identi-
fied variants of potential clinical significance in known disease
genes in 14/271 (5.2%) of new cases. These genes were KIF1A (two
cases with pathogenic variants, one confirmed de novo), L1CAM
(X-linked likely pathogenic variant), MAST1 (two cases with
variants of uncertain significance), HUWE1 (two cases with variants
of uncertain significance), BRWD3 (one case with variant of
uncertain significance), COL4A1 (three cases, one with a patho-
genic variant, two with variants of uncertain significance),
SYNGAP1 (one case with a variant of uncertain significance) and
NT5C2 (homozygous pathogenic variant, identical by descent). We
also identified a de novo variant in SCN8A, which was shared by a
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this as a variant of uncertain significance based on the known
broad clinical spectrum and expressivity of SCN8A mutations.43,44
The identification of variants in genes known to cause other
neurodevelopmental problems in individuals with CP is not
surprising given the frequency of comorbidity of these develop-
mental disabilities; however, this should not change the original
CP diagnosis, which is based on defined clinical inclusion and
exclusion criteria and not genetic criteria.45 There are three likely
contributing and non-exclusive explanations for the high
frequency of variation in known disease genes in CP cohorts:
firstly, many of the genes associated with neurodevelopmental
disorders are likely to have as yet incompletely reported
phenotypic spectrums; secondly the observed clinical phenotypes
may represent blended phenotypes resulting from multiple
genetic hits; and thirdly, there is ascertainment bias inherent in
genetic investigations of neurodevelopmental disorders depen-
dent on the specific criteria on which recruitment was based due
to the frequent co-occurrence of multiple neurodevelopmental
phenotypes. Rather than suggesting incorrect inclusion of an
individual in a CP cohort, we argue that these findings further
highlight the utility of genomics for accurate diagnosis in
individuals with CP.
In the total cohort of 366 cases, three individuals with variants
of uncertain significance in MAOB were identified, including a
female, P915, with a clinically discordant monozygotic twin. MAOB
is a monoamine oxidase, which catalyses the oxidative deamina-
tion of neuroactive and vasoactive amines, as well as the oxidation
of several xenobiotics. It is a highly environmentally responsive
gene and has been shown to be differentially methylated in
response to some environmental stressors, for example smok-
ing;46 therefore, localised changes to methylation caused by
environmental differences between the twins could explain the
clinical discordance. Of note, there was reported twin-to-twin
transfusion syndrome (TTTS) during pregnancy, with P915 being
plethoric and polycythaemic after birth and requiring photo-
therapy, while her twin had no reported neurological sequelae. A
second discordant monozygotic twin pair included in this study,
P904 and his twin, were found to both carry a de novo rare variant
of uncertain significance in SCN8A (SCN8A p.A1575V), with TTTS
also detected in their mother’s pregnancy. Monozygotic twins,
particularly clinically discordant twin pairs, offer a unique and
powerful tool to examine the relative contributions of genetics
and environment to CP aetiology. Intrauterine environmental
differences, such as those resulting from TTTS and placenta
sharing, or postzygotic genetic variation likely account for the
extreme differences in clinical outcome and warrant closer
examination.
One gene, AGAP1, showed both a statistically significant burden
of rare variants and an overabundance of rare, likely deleterious
variants, including two de novo variants. AGAP1 is a
phosphoinositide-dependent Arf GAP that affects the actin
cytoskeleton, as well as localising to endosomes where it alters
stress fibres,47 and is therefore thought to link endocytic traffic to
the actin cytoskeleton. Both overexpression and downregulation
of AGAP1 have been shown to affect neuronal endosomal
trafficking and dendritic spine morphology in mouse primary
neurons.31 Rare variants in AGAP1 have also been previously
implicated in autism48 and suggested as a risk factor for
schizophrenia.31 We demonstrated that AGAP1 morphant zebra-
fish have reduced startle and escape responses, reduced motility
and developmental delay, further supporting a role for AGAP1 in
neurodevelopment.
We have previously reported recurrent genetic variance in
TUBA1A and L1CAM in an unselected cohort of CP cases.15 We
identified one additional likely pathogenic X-linked L1CAM variant
in this cohort, confirming its status as a recurrent CP gene;
however, the HaloPlex gene panel achieved poor coverage of
TUBA1A (Supplementary Table 2), and therefore we were unable to
Fig. 1 Scatterplots of CADD Phred vs PolyPhen2 scores for variants in genes with an overrepresentation of pathogenic variants in cerebral
palsy cases compared to 1000 genomes controls. Controls—filled dots, CP cases—crossed dots
C. L. van Eyk et al.
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Fig. 2 AGAP1 morphant zebrafish show gross developmental defects, neurological deficits and reduced motility. a Representative images of
developmental phenotypes observed at 24 hpf and 72 hpf in AGAP1 morphant zebrafish larvae. At 24 hpf, we frequently observed gross
developmental delay, including reduced pigment, with some larvae exhibiting necrosis in the head. At 72 hpf, AGAP1 morphant larvae
frequently showed milder developmental delay and a curved tail. b, c Phenotype frequencies observed in morphant larvae at 24 and 48 hpf,
respectively. AGAP1 morpholino was injected in a concentration range to assess dosage dependence of the phenotypes in morphant larvae.
d–g AGAP1 morphant larvae show decreased activity and reduced escape response to stimuli at 96 hpf, which is partially rescued by co-
injection of human AGAP1 mRNA. CTRLMO+ CTRLmRNA; n= 48, CTRLMO+ AGAP1MO; n= 42, AGAP1MO+ CTRLmRNA; n= 40, AGAP1MO+
AGAP1mRNA; n= 24. d AGAP1 morphant larvae (dark grey) show reduced activity compared to controls during 1min in the dark (p= 0.0002).
Larvae co-injected with human AGAP1 mRNA and AGAP1 morpholino (light grey, rescue) show significantly greater activity than AGAP1
morphants (p < 0.0001). There is no significant difference in activity between AGAP1 morphants co-injected with human AGAP1 mRNA (light
grey, rescue) and either control. Complete statistics can be found in Supplementary Table 9. e AGAP1 morphant larvae display both a reduced
escape response and an altered trajectory in the 250ms following tap stimulation compared to larvae co-injected with Control morpholino
and either Control mRNA or human AGAP1 mRNA. Larvae co-injected with AGAP1 morpholino and human AGAP1 mRNA show an increased
reaction compared to both controls. Complete statistics can be found in Supplementary Table 10. ***p < 0.001; ns, not significant. f Activity of
larvae measured over a time course in darkness and then following the light in the apparatus being switched on. Error bars are s.e.m.
g Response to light measured over 250ms following the light stimulus. All groups except AGAP1 morphant larvae display a characteristic
spike in activity immediately following the light stimulus. AGAP1 morphant larvae (black bars) show no significant increase in activity in
response to light (p= 0.426). Error bars are s.e.m. *p < 0.05, **p < 0.01, ***p < 0.001; ns, not significant
C. L. van Eyk et al.
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properly assess recurrence. In addition, the relatively low number
of complete parent–child trios (45/271 for naïve cases) available
for confirmation of variant segregation in this study made
interpretation of many genetic variants difficult; therefore, we
have likely underestimated the true recurrence of causative
genetic variation in genes tested in this gene panel.
We identified a large number of variants of uncertain
significance (VUS), including single hit rare or novel likely
deleterious variants in genes that have been associated with
autosomal recessive disorders (Supplementary Table 1), and rare
or novel variants inherited from an unaffected parent that are
associated with a dominant genetic disorder. A further class was
unable to be classified due to unavailability of parental samples
for segregation analysis. The interpretation of VUS in CP is made
significantly more complex by both the high level of clinical
heterogeneity amongst affected individuals and the likely inter-
play of environmental and genetic factors. While selecting likely
monogenic cases of CP with mutations in known disease genes
and a clearly consistent clinical picture is relatively straightforward,
the majority of individuals with CP will likely not fall into this
category. It has not escaped our notice that a number of
individuals in whom we have identified potentially causative
genetic variation have additional risk factors or known precipitants
for CP, for example premature birth, intrauterine growth restric-
tion or intraventricular haemorrhage. In some cases, genetic
variation may be the cause of or a contributor to these
precipitants: for example, individuals with COL4A1 mutations have
high susceptibility to intracerebral haemorrhage. The additive
effects of a less damaging mutation coupled with an environ-
mental insult may be responsible in other cases. Larger cohort
studies will also be required to address the contribution of
common genetic variation, in combination with environmental
factors, to CP burden. Additional factors such as variable
penetrance and clinical variability of mutations in some genes,
as well as the potential for polygenic aetiology in some cases, will
also need to be addressed.
Excluding cases previously investigated using WES, 27/271
(10%) of individuals in this cohort were found to harbour a variant
of possible clinical relevance in a known disease gene or variation
intolerant candidate gene (Tables 1 and 2). Together with our
previous study,15 these data highlight several genes as key CP
genes, which should be considered as part of a genetic diagnosis
for individuals with CP. In our aggregate cohort of 489 clinically
unselected individuals with CP (this study and ref. 15), six
individuals with variants of potential clinical significance have
been identified in COL4A1, three individuals with variants in each
of L1CAM, KIF1A, MAOB and AGAP1, and two individuals with
TUBA1A variants, therefore these six genes alone may contribute
at least 4% of disease burden to CP. Additional functional studies
are required to confirm the disease association of the novel
candidate genes MAOB and AGAP1. Genetic diagnoses have
important implications both for clinical management of the
individual patient and family planning. Our data demonstrate




All study samples were obtained from the DNA Biobank of the Australian
Collaborative Cerebral Palsy Research Group and written informed consent
was given, either by the participant or their guardian, for the use of their
sample. This study was approved by the Women’s and Children’s Health
Network (WCHN) Human Research Ethics Committee (reference number:
HREC/15/WCH/148). Each case was confirmed to fit the published inclusion
criteria for CP49,50 by a paediatric rehabilitation specialist at the time of
recruitment to the Biobank or to the state-based CP registers. Cases were
otherwise clinically unselected. Clinical information was obtained by
completion of a questionnaire by the participant or their guardian and
clinical review by a treating clinician. Where clinical review was not
possible, or where discrepancies between the questionnaire and the
clinical review were identified, patient case notes were reviewed.
HaloPlex gene panel design
The CP gene panel was custom-designed using the HaloPlex Design
Wizard. The total target region size is 388,046 bp, with 384,858 bp of target
bases analysable (99.44% target coverage). It includes 19,989 amplicons
covering a total of 112 candidate genes (see Supplementary Table 1).
DNA extraction
Genomic DNA was either extracted from patient-derived lymphoblastoid
cell lines (LCLs) at Genetic Repositories Australia (GRA, Sydney, Australia),
extracted from blood samples at the Australian Genomics Research Facility
(AGRF), or extracted from buccal samples as previously described.51 DNA
integrity and quantity were verified by gel electrophoresis and Qubit
dsDNA assay (Life Technologies).
HaloPlex protocol
HaloPlex panel library preps were performed according to manufacturer’s
instructions. Briefly, genomic DNA from patient derived LCLs or buccal
samples (225 ng of gDNA) was digested with 16 different restriction
enzymes at 37 °C for 30min to create a library of gDNA restriction
fragments. Following digestion, restriction fragment libraries were
analysed using the 2100 Bioanalyzer (Agilent Technologies Inc., Santa
Clara, CA, USA) to confirm appropriate digestion. Fragments were then
selectively hybridised for 3 h to biotinylated HaloPlex probes (Agilent
Technologies Inc., Santa Clara, CA, USA) from the custom-designed CP
gene panel in the presence of HaloPlex indexes and sequencing motifs.
Circularised target DNA-HaloPlex probe hybrids containing biotin were
then captured by HaloPlex Magnetic Beads on the Agencourt SPRIPlate
Super magnet magnetic plate. DNA ligase was added to close the nicks in
the hybrids, and freshly prepared 50mM NaOH was used to elute the
captured target libraries. The target libraries were amplified (98 °C 2min,
18 cycles of 98 °C 30 s, 60 °C 30 s, 72 °C 1min, then 72 °C for 10min) and
purified using AxyPrep Magnetic beads (Axygen). Amplicons ranging from
175 to 625 bp were then quantified using an Agilent BioAnalyzer High
Sensitivity DNA Assay kit on the 2100 Bioanalyzer to validate the
enrichment of the libraries prior to pooling for multiplexed sequencing.
Sequencing was performed at the ACRF Cancer Genomics Facility
(Adelaide, Australia) either on the Illumina HiSeq 2500 platform with
100 bp paired end reads or the Illumina NextSeq 500 with 150 bp paired
end reads.
HaloPlex sequence analysis
Trimming (to remove low-quality bases from the ends of reads, remove
adaptor sequences and mask enzyme footprints), alignment to the
genome and variant calling were performed using the standard settings
for HaloPlex in the SureCall software (V3.0.1.4, Agilent). Samples were
considered failed and removed from analysis if <50% of targeted bases
were covered by at least 20 reads. Variant call format files were then
exported for annotation by ANNOVAR.52
Variant filtering and prioritisation
Variants were initially hard filtered based on population frequency (using
ExAC frequency < 0.0001 and 1000 genomes frequency < 0.001), evolu-
tionary conservation of the variant residue (using Genomic Evolutionary
Rate Profiling (GERP) score > 4)53 and predicted functional effect (using
Combined Annotation Dependent Depletion (CADD) Phred score > 20
where available).54 Clinically reportable variants: Following hard filtering of
variants, we applied ACMG guidelines to identify variants that would be
considered pathogenic or likely pathogenic in a diagnostic laboratory.
Variants that fit these criteria are denoted by ACMG classifications “likely
pathogenic” or “pathogenic” in Table 1. Research variants: We also
considered a further category of variants that did not meet criteria to be
classified as “pathogenic” or “likely pathogenic” by ACMG guidelines, but
are candidate novel CP variants of research interest. For this purpose,
variants meeting the initial hard filtering thresholds were further prioritised
for validation by predicted functional effect using the following criteria:
Missense Tolerance Ratio < 25th percentile,55 PolyPhen2 prediction of
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probably damaging or possibly damaging56 and MutationTaster prediction
of disease causing.57 A further group of hard filtered variants which met 2/
3 of the prioritisation criteria were validated based on additional support,
e.g. predicted genic intolerance to variation or available clinical data.
Candidate genes were considered intolerant to variation if three or more of
the following criteria were met: DOMINO probability of being autosomal
dominant > 0.5,30 Haploinsufficiency index percentile < 25th,58 ExAC v2
RVIS < 25%,59 pLI > 0.9 and Constraint metric (Z-score Missense) > 2.60
Statistical significance of rare missense variants
In order to test the significance of finding a particular number of rare
missense variants in any gene in our targeted CP gene panel, we used
SORVA.61 Of the 271 new cases included in this study, 209/271 (77%)
reported both parents EUR, with a further 26/271 (9.6%) reporting one
parent EUR (for 24/26 of these, the other parent was either not reported or
unknown). A further 24/271 (8.9%) did not report ethnicity. A small number
of individuals reported East Asian (4/271, 1.5%), South Asian (3/271, 1.1%),
Australian Aboriginal/Torres Strait Islander (1/271, 0.4%) or Polynesian (2/
271, 0.7%) ethnic background. We therefore selected the EUR population
from the 1000 genomes project as the most appropriate for statistical
analysis of the frequency of rare missense variants in our dataset. After
calculating the observed number of rare mutations in the 503 individuals
in the EUR population for each gene in our panel (parameters set to:
protein consequence missense or LOF, population EUR, MAF < 0.001,
Binarity Binary and Zygosity Both), we then calculated the significance of
detecting the number of rare variants identified in the 271 individuals
sequenced in this study for each gene (Bonferroni corrected for the
number of genes sequenced). Bonferroni corrected p-values < 0.05 were
considered to reach genome-wide significance.
To identify genes with a significant overabundance of rare, likely
deleterious variants in CP cases, we extracted variant data for regions
included in the HaloPlex gene panel design for 403 samples from the 1000
genomes EUR dataset. We then annotated variants in these regions with
ANNOVAR. Variants for CP cases and 1000 genome controls were then
filtered for variant frequency (using ExAC frequency < 0.0001 and 1000
genomes frequency < 0.001) and CADD score > 20. The number of variants
meeting these cut-offs for 1000 genome controls was considered the
expected count of pathogenic variants. A binomial test (α= 0.05, two-
tailed test) was performed (GraphPad Prism) comparing the frequency of
CP cases harbouring a pathogenic variant (observed) to the frequency of
control individuals harbouring a pathogenic variant (expected).
Variant validation
All reported variants were validated by Sanger sequencing using BigDye
terminator chemistry 3.1 (ABI) and analysed using a 3730xl genetic
analyzer (Applied Biosystems, Foster City, CA, USA). Sequencing data were
analysed using DNASTAR Lasergene 10 Seqman Pro8 (DNASTAR, Inc.,
Madison, WI, USA). Where possible, DNA from blood or buccal samples was
used for validation, and segregation in patient–parent trios was performed
to confirm the inheritance pattern of the variants. For the 271 new cases
described in this study, 55 had no parental DNA available, 171 had DNA
available for one parent and 45 were complete parent–child trios.
Zebrafish husbandry
All experiments using zebrafish were conducted under the auspices of the
Animal Ethics Committee of the University of Adelaide (project numbers S-
2017-073 and S-2017-089). Danio rerio were bred and maintained at 28.5 °C
on a 14-h light/10-h dark cycle. Embryos were collected from natural
mating of the Tübingen strain (Tu), grown in E3 medium,62 and staged.
Zebrafish morpholino and mRNA injections
Morpholinos were synthesised by Gene Tools LLC (Corvallis, OR, USA).
Stock solutions of morpholinos were made up in sterile water for further
dilution to working concentration immediately prior to injection.
Sequences for morpholinos are:
5′ TCGCCAGGTGCTGCTGATAATTCAT 3′ AGAP1 translation blocker;
5′ CCTCTTACCTCAGTTACAATTTATA 3′ standard control.
The human AGAP1 ORF clone for mRNA production was engineered by
PCR from a cDNA clone (Dharmacon, Clone ID 9021724, Accession
BC140856) with primers designed to add EcoRI and NotI restriction enzyme
sites to the 5′ and 3′ ends of the ORF, respectively (EcoRI-AGAP1 ORF and
NotI-AGAP1 ORF). Following PCR and restriction digest with EcoRI and NotI,
AGAP1 ORF was subcloned into the pcGlobin zebrafish expression
vector.63 The control mRNA construct was generated by PCR amplifying
the ORF of TUBA1A from a cDNA clone (Dharmacon, Clone ID 6050536)
with primers incorporating a 5′ BamHI and a TAA stop codon 4 amino acids
into the encoded protein, and directly ligating the product into pGEM-T
Easy vector (Promega) (TUBA1A-TAA Fw and Rv).
The resultant pGEM-T clone was then digested with BamHI and NotI
restriction enzymes and the TUBA1A-TAA insert was ligated into the
pcGlobin zebrafish expression vector.
The pcGlobin-AGAP1 and pcGlobin-TUBA1A-TAA clones were then used
for generating capped mRNA with the mMessage mMachine T7 Ultra kit
(Ambion Inc., Austin, TX, USA) as per manufacturer’s instructions. Capped
mRNAs were precipitated with LiCl and then redissolved in water for
injection.
Fertilised zebrafish eggs were rinsed in E3 embryo medium and injected
before cleavage. The maximum concentration of experimental morpholino
injected was 1mM (24 ng of morpholino). For rescue experiments, Control
and AGAP1 morpholinos were injected at 250 µM concentration (6 ng of
total morpholino) and messenger RNAs were injected at 100 ng/µl (0.3 ng
of total RNA). Morpholinos were co-injected with mRNA before first
cleavage. Embryos which were not fertilised were discarded at 6 hpf.
Zebrafish DanioVision assays
Larval activity was assayed at 4 days post fertilisation (dpf) using the
DanioVision Observation Chamber (Noldus), which was fitted with a Basler
GenICam camera, independent light source, temperature control unit (set
to 28.5 °C) and tapping device. Individual embryos were placed in each
well of a 96-well tray in pre-warmed embryo medium, then placed in a
dark incubator set to 28.5 °C to acclimatise for at least 30 min before
behavioural testing. The settings used for tracking experiments were
defined using EthoVisionXT software (Version 11.5). Briefly, zebrafish were
in darkness for 5 min, then subjected to two maximum intensity taps 10 s
apart. After a delay of 1 min, the lights were switched on and zebrafish
were assayed in light at 50% intensity for a further 3 min before the trial
ended. Trials were run in triplicate and wells where tracking failed were
excluded from analysis.
Imaging
Embryos were examined at 24 hpf and any dead embryos were removed.
Larvae were examined at 4 dpf and scored for morphological abnormal-
ities. Larvae were imaged after activity assays using a Nikon SMZ1000
dissecting microscope with a Leica DFC450 C camera and Leica Application
Suite software.
Statistical analysis of zebrafish activity
Box-and-whisker plots of distance moved were generated using the
standard method to calculate 5th and 95th percentiles, with data falling
outside this range plotted as individual data points. Differences in distance
moved during 1 min in darkness were tested using the Kruskal–Wallis test
to account for unequal variance, with corrections for multiple comparisons
made using Dunn’s method. Multiplicity adjusted p-values are reported.
Differences in trajectory were tested using χ2 tests to compare the
observed versus expected distribution of categorical data. Differences in
activity before and after lights came on were tested for each treatment
group using a paired t-test. GraphPad Prism was used to generate figures
and perform statistical analyses.
X-chromosome inactivation analysis
X-chromosome inactivation was tested by DNA digestion with the
methylation sensitive restriction enzyme HpaII, and PCR amplification of
digested and undigested samples at the highly polymorphic FRAXA and
AR loci. Briefly, genomic DNA was digested for 24 h at 37 °C before the
HpaII enzyme was heat inactivated at 65 °C. PCRs were then performed
with Hex fluorescently labelled FRAXA primers or FAM fluorescently
labelled AR primers. Fragments from both digested and undigested
samples were sized and quantified using an ABI 3100 genotyper to detect
skewing.
Primer sequences
EcoRI-AGAP1 ORF 5′ GAATTCATGAACTACCAGCAGCAGCTGGCCAAC 3′
NotI-AGAP1 ORF 5′ GCGGCCGCTCAGATGATGGTGGGCACCCTCCCA 3′
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TUBA1A TAA Fw 5′ GGATCCAATGCGTGAGTAAATCTCCATCCA 3′
TUBA1A TAA Rv 5′ GAGCTCTTAGTATTCCTCTCCTTCTTCCTC 3′
FRAXA Fw 5′ GCTCAGCTCCGTTTCGGTTTCACTTCCGGT 3′
FRAXA Rv 5′ AGCCCCGCACTTCCACCACCAGCTCCTCCA 3′
AR Fw 5′ TCCAGAATCTGTTCCAGAGCGTGC 3′
AR Rv 5′ GCTGTGAAGGTTGCTGTTCCTCAT 3′
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
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